92 related articles for article (PubMed ID: 3791250)
1. Clinical pharmacology of mitoxantrone.
Ehninger G; Proksch B; Heinzel G; Woodward DL
Cancer Treat Rep; 1986 Dec; 70(12):1373-8. PubMed ID: 3791250
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of mitoxantrone].
Ogawa M; Sampi K; Tsukui T; Oguro M; Sakai K
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3028-33. PubMed ID: 3767389
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and metabolism of mitoxantrone in man.
Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
[TBL] [Abstract][Full Text] [Related]
4. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
[TBL] [Abstract][Full Text] [Related]
5. Disposition of mitoxantrone in cancer patients.
Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
[TBL] [Abstract][Full Text] [Related]
6. Excretion and metabolism of mitoxantrone in rabbits.
Richard B; Fabre G; Fabre I; Cano JP
Cancer Res; 1989 Feb; 49(4):833-7. PubMed ID: 2912555
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of homoharringtonine.
Savaraj N; Lu K; Dimery I; Feun LG; Burgess M; Keating M; Loo TL
Cancer Treat Rep; 1986 Dec; 70(12):1403-7. PubMed ID: 3791253
[TBL] [Abstract][Full Text] [Related]
8. Isolation and structure elucidation of urinary metabolites of mitoxantrone.
Blanz J; Mewes K; Ehninger G; Proksch B; Greger B; Waidelich D; Zeller KP
Cancer Res; 1991 Jul; 51(13):3427-33. PubMed ID: 2054783
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of mitoxantrone. A review.
Ehninger G; Schuler U; Proksch B; Zeller KP; Blanz J
Clin Pharmacokinet; 1990 May; 18(5):365-80. PubMed ID: 2185907
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer.
Rentsch KM; Schwendener RA; Pestalozzi BC; Sauter C; Wunderli-Allenspach H; Hänseler E
Eur J Clin Pharmacol; 1998 Mar; 54(1):83-9. PubMed ID: 9591936
[TBL] [Abstract][Full Text] [Related]
11. [The effect of infusion rate on pharmacokinetic parameters of azlocillin and mezlocillin].
Haen E; Remien J; Richter E; Frank U; Adam D
Arzneimittelforschung; 1985; 35(5):864-8. PubMed ID: 4026911
[TBL] [Abstract][Full Text] [Related]
12. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of mitoxantrone in man and laboratory animals.
Batra VK; Morrison JA; Woodward DL; Siverd NS; Yacobi A
Drug Metab Rev; 1986; 17(3-4):311-29. PubMed ID: 3552542
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.
Longnecker SM; Donehower RC; Cates AE; Chen TL; Brundrett RB; Grochow LB; Ettinger DS; Colvin M
Cancer Treat Rep; 1987 Jan; 71(1):53-9. PubMed ID: 2878719
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
16. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Canal P; Attal M; Chatelut E; Guichard S; Huguet F; Muller C; Schlaifer D; Laurent G; Houin G; Bugat R
Cancer Res; 1993 Oct; 53(20):4850-4. PubMed ID: 8402672
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ametantrone acetate (NSC-287513).
Kuhn JG; Balmer CE; Ludden TM; Loesch DM; Von Hoff DD; Bender JF; Grillo-Lopez AJ
Cancer Chemother Pharmacol; 1987; 19(2):133-7. PubMed ID: 3568271
[TBL] [Abstract][Full Text] [Related]
19. Clinical and clinical pharmacologic studies of mitoxantrone.
Stewart JA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
